Compare · FMS vs MCTA
FMS vs MCTA
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Charming Medical Limited (MCTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and MCTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS carries a market cap of $12.17B.
- Over the past year, FMS is down 23.9% and MCTA is up 266.5% - MCTA leads by 290.5 points.
- FMS has hit the wire 9 times in the past 4 weeks while MCTA has been quiet.
- FMS has more recent analyst coverage (21 ratings vs 0 for MCTA).
- Company
- Fresenius Medical Care AG
- Charming Medical Limited
- Price
- $21.79-1.04%
- $29.14+7.01%
- Market cap
- $12.17B
- -
- 1M return
- +0.65%
- +0.00%
- 1Y return
- -23.95%
- +266.54%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 9
- 0
- Recent ratings
- 21
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
- SEC Form SD filed by Fresenius Medical Care AG
- Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
- Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
- Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
- SEC Form 6-K filed by Fresenius Medical Care AG
Latest MCTA
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 3 filed by new insider Yu Shu Tai Victor
- SEC Form 3 filed by new insider Wong Kit Christine
- SEC Form 3 filed by new insider Cheung Ching Man
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited
- Nasdaq Halts Charming Medical Limited